BioNTech

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection.

Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant

Pharmaceutical giant BioNTech, which worked with Pfizer to create their mRNA coronavirus vaccine, told German news weekly Der Spiegel in an interview published Friday that it would be seeking FDA approval “over the next few weeks” for use of its vaccine in children ages 5 to 11.

Israel’s prime minister has announced that the country will offer a coronavirus booster to people over 60 who have already been vaccinated